Candel therapeutics announces initial positive interim data from randomized phase 2 clinical trial of can-2409 in non-metastatic pancreatic cancer

Needham, mass., nov. 03, 2023 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced initial positive interim survival and immunological biomarker data from the ongoing randomized phase 2 clinical trial of can-2409 plus valacyclovir (prodrug) together with standard of care (soc) chemoradiation followed by resection for borderline resectable pancreatic ductal adenocarcinoma (pdac). data were presented today in a poster session titled ‘neoadjuvant can-2409+prodrug plus chemoradiation for borderline resectable or locally advanced non-metastatic pancreatic adenocarcinoma (pdac) at the 2023 society for immunotherapy (sitc) annual meeting.
CADL Ratings Summary
CADL Quant Ranking